Why public health agencies are turning to generative AI
A new initiative called PULSE will let 10 US public health jurisdictions trial generative AI tools from OpenAI and Anthropic. The goal? Figure out what works — and what doesn’t — before the technology spreads further.
The program, formally named the Public Health Use Case and Learning Scaling Engine, is backed by the Coalition for Health AI (CHAI), Accenture, and the two AI companies. It will run across state, local, tribal, and territorial health agencies.
OpenAI and Anthropic have each donated 10 enterprise licenses, giving up to 2,000 public health practitioners access to their commercial AI products. Accenture will handle participant onboarding and help build playbooks from the trial results.
“Every major technological transformation succeeds or fails based on trust, governance and execution,” said Dr. David Lakey, former Texas health commissioner, in a statement. “PULSE will support agencies in this endeavour, and is specifically designed for practical implementation.”
Five focus areas for the pilot
CHAI’s leadership council will pick the participating jurisdictions. Practitioners will then be grouped into communities tackling five specific use cases:
- Biosurveillance and drug-wave prediction — spotting disease outbreaks and tracking illicit drug trends.
- Social determinants of health (SDoH) mapping — using AI to identify how housing, income, and environment affect community health.
- Operations and community-feedback analysis — automating the review of public comments and internal workflows.
- Public communications and multilingual translation — generating health messages in multiple languages.
- Automated clinical-data retrieval and FHIR query engine — pulling electronic health records using the FHIR standard.
Notably, CHAI hasn’t specified which OpenAI or Anthropic products will be used, nor the model versions or configurations. The announcement also leaves unclear how the two providers will be assigned across the pilots.
What about FHIR and human oversight?
FHIR — an HL7 standard for exchanging healthcare data electronically — features in the clinical-data retrieval use case. But the announcement doesn’t define exactly how generative AI fits into that workflow. Will the models write queries, fetch records, summarize results, or do all three?
It also doesn’t say whether staff will check for incorrect queries, incomplete retrievals, or unsupported summaries before using the information. That’s a critical gap, especially for applications that could involve demographic, geographic, clinical, or population-health data.
CHAI hasn’t disclosed whether the pilots will use identifiable records, de-identified information, synthetic data, or aggregated datasets. That distinction matters for compliance with the US Health Insurance Portability and Accountability Act (HIPAA).
HIPAA and data protection: what’s missing
The US Department of Health and Human Services requires organizations covered by HIPAA to protect electronic health information. Its cloud-computing guidance says regulated entities and service providers must meet HIPAA rules when cloud systems create, receive, maintain, or transmit electronic protected health information.
But HIPAA won’t apply to every PULSE participant or workflow — it depends on the agency, the data involved, and the function being performed. The announcement doesn’t set out retention periods, access controls, audit arrangements, or rules for submitting protected health information.
OpenAI says inputs and outputs from its business services — including ChatGPT Enterprise and its API — are not used to train or improve its models by default. Anthropic makes a similar claim. However, those policies don’t define how the PULSE deployments will be configured in practice.
“We believe AI should be useful, safe and accessible to the people tackling society’s most important challenges,” said Felipe Millon, OpenAI’s head of government go-to-market. He added that the donated licenses were designed to help public health organizations evaluate the tools through a structured process.
Governance and evaluation remain vague
The pilots are scheduled to begin in autumn 2026. CHAI expects to release the resulting playbooks in 2027, which other public health agencies can use as reference material.
But CHAI hasn’t published the measures it will use to assess the pilots. It hasn’t explained whether each use case will be evaluated under separate technical, operational, privacy, and safety criteria. The announcement also doesn’t detail how model outputs will be reviewed — whether staff must approve generated public communications, verify translations, validate retrieved clinical information, or check biosurveillance outputs before use.
The US National Institute of Standards and Technology (NIST) recommends identifying which AI functions need human oversight and training users to understand system performance and limitations. Its generative AI guidance also covers testing, validation, monitoring, documentation, privacy, and management oversight.
“Public health teams are being asked to do more with less, and AI can help — as long as it’s brought in with care and the right guardrails,” said Elizabeth Kelly, Anthropic’s head of beneficial deployments. She said PULSE would let practitioners test the tools in their own environments with privacy, governance, and responsible-use measures built in from the start.
Who can participate — and what’s still unknown
Eligible participants include state and territorial health departments, county and municipal agencies, tribal authorities, Indian health organizations, and large city health departments. But CHAI hasn’t specified minimum staffing, infrastructure, interoperability, or cybersecurity requirements for participating jurisdictions.
Data from the National Association of County and City Health Officials, cited by CHAI, shows nearly 40% of local health departments aren’t using AI at all. The coalition said some departments are interested in revising workflows and improving operational efficiency.
PULSE plans to convert findings from 10 jurisdictions into guidance for wider use. Yet the announcement doesn’t explain how the playbooks will account for differences in agency size, technical systems, legal responsibilities, staffing, or procurement arrangements.
It also doesn’t say whether outputs from biosurveillance, drug-wave prediction, or clinical-data retrieval will be used only for testing, presented to staff for review, or incorporated into operational workflows.
“We know AI is going to reshape how we deliver public health — the question is whether we do it thoughtfully or not,” said Dr. Ashish Jha, a former White House COVID-19 response coordinator. He said the program would test which applications work and document the findings for other agencies.
Broader context: CHAI’s governance work
PULSE is part of CHAI’s larger effort on governance standards for healthcare AI. In May, the organization announced plans to develop guidance covering eight governance areas through workshops and working groups involving more than 150 healthcare AI representatives. It has since started publishing playbooks on organizational AI policies, governance structures, and internal resources.
Separately, CHAI has worked with the Joint Commission on governance playbooks aligned with its voluntary Responsible Use of AI in Healthcare certification. The PULSE announcement doesn’t state that participating public health agencies will be assessed under that certification.
Dr. Brian Anderson, chief executive of CHAI, said public health agencies entered the COVID-19 pandemic after years of limited investment in technology. He said PULSE was intended to give agencies practical experience with AI before wider implementation.
For more on how AI is being applied in healthcare settings, read our coverage of Bunkerhill’s $55M raise for agentic AI across health systems. And if you’re interested in the broader AI landscape, check out our analysis of AI and big data trends in healthcare.